Navigation Links
Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Date:9/11/2008

EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.

The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:

-- Date: Tuesday, September 16, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-874-1565 U.S. & Canada / 719-325-4822 International

The web cast can be accessed online at: http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764

The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies CEO to Retire on December 31, 2008
3. Neurobiological Technologies Reports Third Quarter Financial Results
4. Neurobiological Technologies Sets Date for Third Quarter Financial Results
5. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
7. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
8. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
9. Neurobiological Technologies Sets Date for Research and Development Day
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
11. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... Linda, Ca (PRWEB) , ... August 09, 2017 ... ... exosomes for regenerative medicine applications in the clinic is here. The team at ... EVs present in conditioned medium for clinical studies. , Dr. Travis Antes, ...
(Date:8/10/2017)... USA (PRWEB) , ... August 09, 2017 , ... ... partnered with four international biomedical optics laboratories — the Wellman Center for Photomedicine, ... Medical Laser Center Lübeck and the Beckman Laser Institute at University of California, ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... market news outlet had initiated coverage on Next Group Holdings, Inc. and see's ... consumer markets geared toward those that cannot engage in traditional banking services. According ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme Inc., a leading supplier ... announced the launch of HumanKine® Interferon beta (IFN beta) expressed from ... activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):